Here are the DEF 14A proxy statements from Vir Biotechnology, Inc. (VIR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIR filings page.
Vir Biotechnology has issued its 2026 definitive proxy for the virtual annual stockholder meeting on May 26, 2026, at 9:00 a.m. Pacific Time. Stockholders will vote on electing three Class I directors to terms ending in 2029, an advisory say-on-pay resolution on named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor for 2026.
The company highlights strong governance practices, including an independent board chair, fully independent key committees and stock ownership guidelines. Its compensation program emphasizes pay-for-performance, with most executive pay at risk and tied to corporate achievements such as advancing the ECLIPSE Phase 3 program, publishing SOLSTICE Week 48 data, and progressing T-cell engager programs.